Neurocrine Biosciences (NBIX) Current Assets (2010 - 2026)

Neurocrine Biosciences' Current Assets history runs 17 years deep, the most recent figure standing at $2.4 billion for Q1 2026.

• Quarterly Current Assets rose 48.73% year-over-year to $2.4 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.4 billion (up 48.73% YoY) and the FY2025 annual result came in at $2.5 billion, up 46.27% from the prior year.
• Current Assets was $2.4 billion for Q1 2026 at Neurocrine Biosciences, down from $2.5 billion in the prior quarter.
• Across five years, Current Assets topped out at $2.5 billion in Q4 2025 and bottomed at $1.0 billion in Q1 2022.
• A 5-year average of $1.7 billion and a median of $1.6 billion in 2023 frame the typical range for Current Assets.
• Annual changes were most pronounced in 2022 — Current Assets jumped 49.41% — and 2025, when it retreated 8.95%.
• Neurocrine Biosciences' Current Assets stood at $1.5 billion in 2022, then rose by 10.56% to $1.6 billion in 2023, then grew by 7.32% to $1.7 billion in 2024, then jumped by 46.27% to $2.5 billion in 2025, then fell by 3.43% to $2.4 billion in 2026.
• Business Quant data shows NBIX's Current Assets at $2.4 billion in Q1 2026, $2.5 billion in Q4 2025, and $2.2 billion in Q3 2025.